ArticleACS synthetic biology2022
Reprogramming Synthetic Cells for Targeted Cancer Therapy.
Article in ACS synthetic biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Integration of substrate-specific enzymes and a peroxide biosensor for detection of glucose, uric acid, and cholesterol.Applied and environmental microbiology · 2026Article
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Microbiome-driven resistance in cervical cancer therapy: from mechanistic dissection to clinical translation.Expert reviews in molecular medicine · 2025Review
- Engineering a drug-inducible pyroptosis platform enables precise tumor suppression in colorectal cancer.Synthetic and systems biotechnology · 2025Article
- Artificial cells and biomimicry cells: A rising star in the fight against cancer.Materials today. Bio · 2025Review
- Engineering Genome-Free Bacterial Cells for Effective SARS-COV-2 Neutralisation.Microbial biotechnology · 2025Article
- Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells.Oncology research · 2025Review
- Internal State of Vesicles Affects Higher Order State of Vesicle Assembly and Interaction.ACS omega · 2024Article
- Efficacy of Feed-Based Genome-Free Bacterial Vaccine AgainstVaccines · 2024Article
- Functional surface expression of immunoglobulin cleavage systems in a candidate Mycoplasma vaccine chassis.Communications biology · 2024Article
- Genome engineering on size reduction and complexity simplification: A review.Journal of advanced research · 2024Review
- A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy.International journal of molecular sciences · 2024Review
- Bacterial therapies at the interface of synthetic biology and nanomedicine.Nature reviews bioengineering · 2024Article
- Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy.Microsystems & nanoengineering · 2024Review
- Biofabrication and biomanufacturing in Ireland and the UK.Bio-design and manufacturing · 2024Review
- A Synthetic Signaling Network Imitating the Action of Immune Cells in Response to Bacterial Metabolism.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Nanobodies: Robust miniprotein binders in biomedicine.Advanced drug delivery reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Advances in synthetic biology enable the reprogramming of bacteria as smart agents to specifically target tumors and locally release anticancer drugs in a highly controlled manner. However, the bench-to-bedside translation of engineered bacteria is often impeded by genetic instability and the potential risk of uncontrollable replication of engineered bacteria inside the patient. SimCells (simple cells) are chromosome-free bacteria controlled by designed gene circuits, which can bypass the interference of the native gene network in bacteria and eliminate the risk of bacterial uncontrolled growth. Here, we describe the reprogramming of SimCells and mini-SimCells to serve as "safe and live drugs" for targeted cancer therapy. We engineer SimCells to display nanobodies on the surface for the binding of carcinoembryonic antigen (CEA), which is an important biomarker found commonly in colorectal cancer cells. We show that SimCells and mini-SimCells with surface display of anti-CEA nanobody can specifically bind CEA-expressing Caco2 cancer cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.